Table 4.
Availability of 15 innovative anti-cancer medicines before and after policy implementation.
| No. | Name | Tertiary hospital/% | Secondary hospital/% | ||
|---|---|---|---|---|---|
| Before | After | Before | After | ||
| 1 | Rituximab | 85.00 | 85.00 | 50.00 | 33.33 |
| 2 | Trastuzumab | 70.00 | 50.00 | 33.33 | 50.00 |
| 3 | Bevacizumab | 45.00 | 85.00 | 33.33 | 83.33 |
| 4 | Sorafenib | 15.00 | 50.00 | 0.00 | 0.00 |
| 5 | Bortezomib | 40.00 | 45.00 | 0.00 | 33.33 |
| 6 | Erlotinib | 45.00 | 55.00 | 0.00 | 50.00 |
| 7 | Nimotuzumab | 30.00 | 40.00 | 0.00 | 0.00 |
| 8 | Apatinib | 40.00 | 55.00 | 0.00 | 33.33 |
| 9 | Chidamide | 0.00 | 20.00 | 0.00 | 0.00 |
| 10 | Fulvestrant | 10.00 | 60.00 | 0.00 | 16.67 |
| 11 | Everolimus | 20.00 | 25.00 | 0.00 | 0.00 |
| 12 | Lenalidomide | 10.00 | 35.00 | 0.00 | 0.00 |
| 13 | Lapatinib | 0.00 | 15.00 | 0.00 | 0.00 |
| 14 | Abiraterone | 0.00 | 35.00 | 0.00 | 33.33 |
| 15 | Recombinant human endostatin | 80.00 | 75.00 | 33.33 | 50.00 |